New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:09 EDTEXELExelixis announces Cometriq approved in Europe
Exelixis announced that the European Commission has approved Cometriq for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma, or MTC. The European Commission granted conditional marketing authorisation following a positive opinion from the European Committee for Medicinal Products for Human Use, or CHMP, issued in December 2013. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions. The Committee for Orphan Medicinal Products also reviewed the designation for Cometriq as an orphan medicinal product for the treatment of MTC, and recommended maintenance of orphan drug designation at the time of marketing authorisation.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
09:23 EDTEXELExelixis files automatic mixed securities shelf
08:46 EDTEXELExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 29, 2015
05:51 EDTEXELStocks with implied volatility movement; XOMA EXEL
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use